Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Receivables - Other (2016 - 2025)

Historic Receivables - Other for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to $1.6 million.

  • Spero Therapeutics' Receivables - Other fell 4098.66% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 4098.66%. This contributed to the annual value of $3.1 million for FY2024, which is 9967.64% up from last year.
  • Spero Therapeutics' Receivables - Other amounted to $1.6 million in Q3 2025, which was down 4098.66% from $2.5 million recorded in Q2 2025.
  • In the past 5 years, Spero Therapeutics' Receivables - Other ranged from a high of $8.5 million in Q1 2021 and a low of $668000.0 during Q1 2025
  • For the 5-year period, Spero Therapeutics' Receivables - Other averaged around $2.6 million, with its median value being $2.1 million (2023).
  • Per our database at Business Quant, Spero Therapeutics' Receivables - Other surged by 22702.41% in 2023 and then tumbled by 8668.53% in 2025.
  • Spero Therapeutics' Receivables - Other (Quarter) stood at $2.6 million in 2021, then plummeted by 58.95% to $1.1 million in 2022, then skyrocketed by 42.53% to $1.5 million in 2023, then soared by 99.68% to $3.1 million in 2024, then plummeted by 48.43% to $1.6 million in 2025.
  • Its Receivables - Other was $1.6 million in Q3 2025, compared to $2.5 million in Q2 2025 and $668000.0 in Q1 2025.